Skin Cancer | Topics

Study investigators indicated that these results call for the need to revise skin cancer health policies to be able to handle the increasing burden of keratinocyte carcinoma management.

A study published in JAMA Dermatology determined that topical immunosuppressant medications used to treat adult patients with atopic dermatitis do not increase the risk of common forms of cancer despite warning labels on the packaging.

Cemiplimab demonstrated an objective response rate of 31% in patients with locally advanced basal cell carcinoma who progress on or are intolerant to hedgehog inhibitors.